GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.37 Average Target Price from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received an average rating of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.37.

Several research analysts have recently commented on the company. Morgan Stanley reduced their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Barclays dropped their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, Citigroup cut their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On GoodRx

A number of large investors have recently added to or reduced their stakes in the company. Fortem Financial Group LLC bought a new stake in shares of GoodRx during the 3rd quarter valued at $772,000. Liontrust Investment Partners LLP bought a new position in shares of GoodRx in the 2nd quarter worth about $520,000. Charles Schwab Investment Management Inc. lifted its position in GoodRx by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after acquiring an additional 26,262 shares during the period. Raymond James & Associates boosted its stake in GoodRx by 212.6% during the third quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock worth $2,734,000 after acquiring an additional 267,951 shares in the last quarter. Finally, Legato Capital Management LLC purchased a new stake in GoodRx in the second quarter worth about $805,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

Shares of GDRX stock opened at $4.52 on Friday. GoodRx has a 12 month low of $4.09 and a 12 month high of $9.26. The company’s fifty day simple moving average is $5.14 and its 200-day simple moving average is $6.86. The firm has a market cap of $1.72 billion, a PE ratio of -150.67, a P/E/G ratio of 3.54 and a beta of 1.29. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.